Merus, which is developing bispecific antibody treatments for solid tumors, raised $55 million by offering 5.5 million shares at $10. It originally planned to offer 4.3 million shares at a range of $14 to $16. Its new market cap of $158 million is a 29% discount to the one proposed when the company set terms. Merus plans to list on the Nasdaq under the symbol MRUS. Citi and Jefferies acted as lead managers on the deal.
